Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02764593 · ClinicalTrials.gov registry record · Phase 1
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
A Phase 1 study, sponsored by RTOG Foundation.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02764593 is a Phase 1 study that has completed, run by RTOG Foundation. The registered enrollment target is 40 participants.
The verdict
NCT02764593, a Phase 1 study, has completed, sponsored by RTOG Foundation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG Cetuximab
- RADIATION IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-06 |
| Est. Completion | 2022-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02764593
The ClinicalTrials.gov registry entry for NCT02764593 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RTOG Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT02764593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02764593 about?
NCT02764593 is a clinical study titled "Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer". This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
What is the current status of trial NCT02764593?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-06. Estimated completion is 2022-02-21.
What interventions are being tested in trial NCT02764593?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), Cetuximab (DRUG), IMRT (RADIATION).
Who is sponsoring clinical trial NCT02764593?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.